AbbVie Seeks Accelerated FDA OK of Teliso-V in Non-Small Cell Lung Cancer
By Colin Kellaher
AbbVie has filed for accelerated Food and Drug Administration approval of its proposed antibody-drug conjugate for patients with a form of lung cancer.
AbbVie on Friday said the application covers telisotuzumab vedotin, or teliso-V, in adults with previously treated, locally advanced or metastatic epidermal growth factor receptor wild type, nonsquamous non-small cell lung cancer with c-Met protein overexpression.
The North Chicago, Ill., biopharmaceutical company said there are currently no approved anti-cancer therapies specifically for c-Met overexpressing non-small cell lung cancer, which is associated with a poor prognosis.
Antibody-drug conjugates, known as ADCs, work like guided missiles by pairing antibodies with toxic agents to fight cancer.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2024 12:48 ET (16:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States